These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28850021)

  • 1. Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.
    Siebuhr AS; Kjelgaard-Petersen CF; Sun S; Byrjalsen I; Christiansen C; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(1):94-101. PubMed ID: 28850021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
    Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
    Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
    Gudmann NS; Junker P; Juhl P; Thudium CS; Siebuhr AS; Byrjalsen I; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(5):829-835. PubMed ID: 29745884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
    Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological identification of fast progressors of structural damage with rheumatoid arthritis.
    Siebuhr AS; Bay-Jensen AC; Leeming DJ; Plat A; Byrjalsen I; Christiansen C; van de Heijde D; Karsdal MA
    Arthritis Res Ther; 2013 Aug; 15(4):R86. PubMed ID: 23945134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
    Kaneko A; Kida D; Saito K; Tsukamoto M; Sato T
    Rheumatol Int; 2012 Nov; 32(11):3631-7. PubMed ID: 22127466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
    Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
    Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
    Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
    Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
    Shiozawa K; Yamane T; Murata M; Yoshihara R; Tsumiyama K; Imura S; Shiozawa S
    Arthritis Res Ther; 2016 Feb; 18():55. PubMed ID: 26922083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study.
    Bay-Jensen AC; Platt A; Byrjalsen I; Vergnoud P; Christiansen C; Karsdal MA
    Semin Arthritis Rheum; 2014 Feb; 43(4):470-8. PubMed ID: 23932312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.